非瓣膜病房颤的抗凝治疗

Anticoagulation of nonvalvular atrial fibrillation

关键词:  非瓣膜病房颤  抗凝  风险量表  亚洲人群  新型口服抗凝药

Key words:  non valvular atrial fibrillation  anticoagulation therapy  risk scores  Asian population  new oral anticoagulation

摘要:

社会老龄化必然带来房颤的高发生率，继之脑卒中的高发生率。口服抗凝药可有效降低脑卒中的发生，有效率达64%。但抗凝药在中国的应用情况一直未能达到令人满意的水平，因此有必要重申卒中风险量表（CHADS2 和CHA2DS2-VASc）的应用，指导规范化的抗凝治疗。同时应注意亚洲人群脑卒中的特殊性，包括出血性卒中高发及抗凝强度宜较白种人低等问题。近些年问世的新型口服抗凝药似乎对亚洲人群尤为有益，又可避免不断抽血化验的烦恼，应予重视及推广。

Abstract:

Aging society is bound to bring about the high incidence of atrial fibrillation, following the high incidence of stroke. Oral anticoagulants can effectively reduce stroke incidence rate of 64%, but anticoagulant drugs application in our country has failed to meet the satisfaction level. Therefore, it is necessary to reiterate the application of stroke risk score （CHADS2 and CHA2DS2-VASC）that standardizes of anticoagulant therapy. While paying attention to Asian patients with higher cerebral stroke incidence include bleeding stroke and anticoagulation intensity should be lower than in westerner. In recent years, the new oral anticoagulants come out seem to be superior in the Asian population is particularly useful, and avoid the trouble of frequently blood tests and should be paid more attention and promotion.